Cervical Co-Test at Chughtai Lab

Cervical Co-Test at Chughtai Lab

The Cervical Co-Test at Chughtai Lab is a premier, comprehensive screening protocol designed for the early detection and prevention of cervical cancer. This advanced diagnostic evaluation combines two distinct medical investigations performed on a single clinical sample: Liquid-Based Cytology (commonly known as the Pap smear or Pap test) and molecular Human Papillomavirus (HPV) DNA testing. By analyzing both cellular morphology and the presence of high-risk viral DNA, the Cervical Co-Test offers unparalleled diagnostic sensitivity, significantly reducing the risk of missing pre-cancerous lesions. Chughtai Lab, a leading diagnostic network in Pakistan, utilizes state-of-the-art laboratory technology and automated molecular platforms to perform this test, ensuring the highest standards of clinical accuracy and reliability for patients across Lahore, Karachi, Islamabad, and other major cities.

Cervical cancer is highly preventable when pre-cancerous changes are identified and managed early. The cervix, which is the lower, narrow part of the uterus connecting to the vagina, is lined with squamous and columnar epithelial cells. The area where these two cell types meet is called the transformation zone, which is highly susceptible to cellular changes (dysplasia) caused by persistent infections with high-risk strains of Human Papillomavirus (HPV). While the cytological component of the Cervical Co-Test evaluates physical changes in these cells under a microscope, the molecular HPV DNA test identifies the genetic material of high-risk HPV genotypes (such as HPV 16 and HPV 18) that are known to cause over 70% of cervical cancers. Together, these two tests provide a complete clinical picture, allowing gynecologists and oncologists to stratify patient risk accurately and establish appropriate surveillance or treatment pathways.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest diagnostic accuracy of the Cervical Co-Test at Chughtai Lab, patients must adhere to specific preparation guidelines. Proper preparation prevents specimen contamination and ensures that an adequate number of clean cervical cells are collected for both cytological and molecular analysis. Please follow these instructions carefully:

• Avoid Vaginal Intercourse: Refrain from sexual intercourse for at least 48 hours prior to the test, as semen and friction can alter cervical cell morphology and interfere with molecular testing.
• Avoid Vaginal Products: Do not use tampons, vaginal creams, lubricants, contraceptive foams, jellies, or douching products for 48 hours before the procedure. These substances can obscure abnormal cells and compromise the liquid-based cytology medium.
• Schedule Around Menstruation: The test should not be performed during active menstrual bleeding, as blood can obscure the microscopic view of cervical cells. The ideal time to schedule the test is 10 to 20 days after the first day of your last menstrual period.
• Hygiene: Maintain normal external hygiene on the day of the test. No special fasting or dietary restrictions are required.
• Inform Your Clinician: Advise the healthcare provider if you are pregnant, have a history of abnormal Pap smears, are currently treating a vaginal infection, or have undergone recent gynecological procedures.

During the Procedure

The collection of the sample for the Cervical Co-Test is a quick, minimally invasive, and outpatient procedure performed in a private, comfortable environment at Chughtai Lab or by your referring gynecologist. The entire procedure takes approximately 5 to 10 minutes:

• Positioning: The patient is asked to lie on an examination table in the lithotomy position, with feet placed in stirrups to allow optimal access to the pelvic region.
• Speculum Insertion: The healthcare provider gently inserts a sterile, lubricated speculum into the vagina. This instrument holds the vaginal walls apart, allowing a clear and direct view of the cervix.
• Sample Collection: Using a specialized, soft plastic broom-like device or a spatula and cytobrush, the clinician gently sweeps the transformation zone of the cervix. This collection process is designed to harvest cells from both the ectocervix and endocervix.
• Specimen Preservation: The collected cells are immediately rinsed and suspended in a vial containing a specialized liquid preservative (Liquid-Based Cytology vial). This liquid medium preserves the cells perfectly, preventing cell clumping and drying artifacts.
• Laboratory Processing: In the Chughtai Lab pathology department, the liquid vial is processed. An automated thin-layer slide is prepared for cytological examination by a consultant pathologist, while the remaining liquid is processed on an automated molecular platform for high-risk HPV DNA PCR testing.
• Patient Experience: Patients may feel a mild sensation of pressure or brief cramping during the cell collection. Some light spotting or discharge may occur immediately after the test, which is normal and typically resolves within 24 hours.

When is a Cervical Co-Test Performed?

1. Routine Cervical Cancer Screening

The primary clinical indication for a Cervical Co-Test is routine cervical cancer screening in women aged 30 to 65 years. International clinical guidelines, including those from the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Colposcopy and Cervical Pathology (ASCCP), recommend co-testing every 5 years for this age group. This extended interval is safe because the combination of a negative Pap smear and a negative high-risk HPV test indicates an extremely low risk of developing cervical cancer or high-grade dysplasia over the subsequent five years.

2. Follow-Up of Borderline or Abnormal Pap Smears

Physicians frequently request a Cervical Co-Test to clarify ambiguous or borderline results from previous cytological screenings. For instance, if a patient previously presented with Atypical Squamous Cells of Undetermined Significance (ASC-US), the addition of molecular HPV testing helps determine whether the cellular changes are due to a high-risk viral infection or benign inflammatory processes. This assists clinicians in deciding whether to refer the patient for a colposcopy or continue routine surveillance.

3. Detection of High-Risk Human Papillomavirus (HPV)

Persistent infection with high-risk HPV genotypes is the single most important risk factor for the development of cervical neoplasia. The Cervical Co-Test is performed to specifically identify the presence of these high-risk viral strains, particularly HPV 16 and HPV 18, which carry the highest oncogenic potential. Identifying these strains early allows for proactive clinical monitoring before physical cellular abnormalities even manifest on the cervix.

4. Evaluation of Unexplained Vaginal Symptoms

While not a primary diagnostic tool for acute infections, a Cervical Co-Test may be requested by gynecologists when evaluating patients presenting with unexplained vaginal symptoms, such as post-coital bleeding, intermenstrual bleeding, or abnormal vaginal discharge. Evaluating the cervix cytologically and virologically helps rule out cervical dysplasia, chronic cervicitis, or malignancy as the underlying cause of these clinical symptoms.

5. Surveillance After Treatment for Cervical Dysplasia

Patients who have undergone treatment for high-grade cervical intraepithelial neoplasia (CIN 2 or CIN 3) or adenocarcinoma in situ require rigorous follow-up. The Cervical Co-Test is utilized as a highly sensitive surveillance tool post-treatment (such as after a LEEP or cold knife cone biopsy) to ensure that the abnormal cells have been completely eradicated and that the high-risk HPV infection has cleared, minimizing the risk of recurrence.

What Does a Cervical Co-Test Detect?

The Cervical Co-Test is highly sensitive and capable of identifying a wide spectrum of cytological, histological, and molecular abnormalities. Specifically, the test detects:

• 1. Negative for Intraepithelial Lesion or Malignancy (NILM): Confirms normal cervical cytology with no evidence of cellular abnormalities, dysplasia, or cancer.
• 2. High-Risk HPV Genotypes: Detects the presence of oncogenic HPV strains, specifically genotyping for HPV 16 and HPV 18.
• 3. Other High-Risk HPV Strains: Identifies the presence of other high-risk viral strains, including HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
• 4. Atypical Squamous Cells of Undetermined Significance (ASC-US): Identifies mildly abnormal squamous cells that do not meet the criteria for a definitive pre-cancerous lesion.
• 5. Low-Grade Squamous Intraepithelial Lesions (LSIL): Detects early, mild cellular changes typically associated with transient, active HPV infections (mild dysplasia or CIN 1).
• 6. High-Grade Squamous Intraepithelial Lesions (HSIL): Detects moderate-to-severe cellular changes that have a high probability of progressing to invasive cervical cancer if left untreated (CIN 2, CIN 3, and CIS).
• 7. Atypical Squamous Cells, Cannot Exclude HSIL (ASC-H): Identifies abnormal squamous cells that carry a high suspicion of representing high-grade dysplasia.
• 8. Squamous Cell Carcinoma: Detects cytological features indicative of invasive squamous cell cervical cancer.
• 9. Atypical Glandular Cells (AGC): Identifies abnormal glandular cells originating from the endocervical canal or endometrium, requiring immediate clinical investigation.
• 10. Adenocarcinoma in Situ (AIS): Detects pre-cancerous lesions originating within the glandular tissues of the endocervix.
• 11. Endocervical Adenocarcinoma: Identifies cytological evidence of invasive glandular cervical cancer.
• 12. Specimen Adequacy: Assesses whether the collected sample contains a sufficient number of well-preserved squamous and endocervical cells for accurate evaluation.
• 13. Koilocytosis: Detects pathognomonic cytological changes (perinuclear halos and nuclear enlargement) characteristic of active HPV infection.
• 14. Inflammation-Induced Cellular Changes: Identifies benign, reactive cellular changes caused by localized inflammation or tissue repair.
• 15. Atrophic Vaginitis: Identifies cellular patterns characteristic of low estrogen levels, common in postmenopausal women.
• 16. Candida Species: Detects fungal structures (pseudohyphae and budding yeast) indicating a vaginal yeast infection.
• 17. Trichomonas vaginalis: Identifies the presence of this parasitic protozoan responsible for trichomoniasis.
• 18. Bacterial Vaginosis: Detects shift in vaginal flora and the presence of “clue cells” indicative of bacterial vaginosis.
• 19. Actinomyces Species: Identifies bacterial colonies often associated with prolonged intrauterine device (IUD) use.
• 20. Herpes Simplex Virus (HSV) Changes: Detects characteristic multinucleation and ground-glass nuclear appearance associated with active HSV infection.
• 21. Hyperkeratosis: Identifies the presence of anucleated squamous cells, reflecting chronic irritation or cervical leukoplakia.
• 22. Parakeratosis: Detects miniature, mature squamous cells reflecting abnormal cornification of the cervical epithelium.
• 23. Endometrial Cells in Postmenopausal Women: Detects the presence of normal-appearing endometrial cells in women over 45, which may require endometrial evaluation.
• 24. Cellular Regeneration: Identifies active tissue healing and repair patterns following localized trauma or infection.
• 25. Radiation-Induced Cellular Changes: Identifies persistent cellular alterations in patients with a history of pelvic radiation therapy.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand the anxiety associated with waiting for diagnostic results. The Cervical Co-Test involves complex, multi-step laboratory processing, including thin-layer slide preparation, microscopic cytological evaluation by a consultant pathologist, and automated molecular PCR amplification for HPV DNA. Consequently, the turnaround time for this comprehensive co-test is typically 3 to 5 working days. Once the report is finalized, patients receive an automated SMS notification. Reports can be easily accessed and downloaded online via the Chughtai Lab official website or the Chughtai Lab mobile application. Physical copies of the report can also be collected from any of our convenient diagnostic centers across Pakistan.

Cervical Co-Test Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Specimen Adequacy	Satisfactory for evaluation; abundant squamous and endocervical cells present.	Unsatisfactory for evaluation due to low cellularity, excessive blood, or severe inflammation.
Squamous Epithelial Cells	Negative for Intraepithelial Lesion or Malignancy (NILM); normal cell morphology.	ASC-US, ASC-H, LSIL, HSIL, or invasive Squamous Cell Carcinoma.
Glandular Epithelial Cells	Normal endocervical and endometrial cells appropriate for patient age.	Atypical Glandular Cells (AGC), Adenocarcinoma in Situ (AIS), or Adenocarcinoma.
High-Risk HPV DNA	Negative (No high-risk HPV DNA detected).	Positive for HPV 16, HPV 18, or other high-risk genotypes (e.g., 31, 33, 45, 52, 58).
Infectious Organisms	Normal vaginal flora; no pathogenic organisms identified.	Presence of Candida, Trichomonas vaginalis, Bacterial Vaginosis (clue cells), or Actinomyces.
Reactive Cellular Changes	Absent or minimal, consistent with healthy tissue.	Moderate to severe reactive changes secondary to inflammation, radiation, or intrauterine devices.
Hormonal Evaluation	Hormonal pattern compatible with age and menstrual history.	Atrophy or discordant hormonal pattern requiring clinical correlation.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Cervical Co-Test?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists and cytotechnologists specializing in gynecological cytology and molecular diagnostics.
• Patient-Focused Care: We prioritize patient comfort, privacy, and dignity, providing a safe and supportive environment for all clinical sample collections.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, participating in rigorous external quality assurance programs.
• Professional Reporting: Our reports are highly detailed, structured according to the standardized Bethesda System, and designed to provide clear, actionable insights for your physician.
• Modern Diagnostic Approach: We utilize state-of-the-art liquid-based cytology (LBC) and automated real-time PCR platforms for highly accurate HPV DNA genotyping.
• Comfortable Environment: Our dedicated female staff and private collection rooms ensure that female patients feel completely at ease during the sample collection process.
• Convenient Location: With an extensive network of diagnostic centers and collection points across Pakistan, accessing our services is easy and convenient.
• Commitment to Accurate Diagnosis: We are dedicated to providing timely, precise, and evidence-based diagnostic results to support effective clinical decision-making and patient care.